Jazz Pharmaceuticals plc Files Amendment to Annual Report

TL;DR

<b>Jazz Pharmaceuticals plc has filed an amendment to its 2023 annual report.</b>

AI Summary

Jazz Pharmaceuticals plc (JAZZ) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. Jazz Pharmaceuticals plc filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The filing was made on April 26, 2024. The company's ordinary shares are traded on The Nasdaq Stock Market LLC under the symbol JAZZ. Jazz Pharmaceuticals plc is incorporated in Ireland. The company's principal executive offices are located in Dublin, Ireland.

Why It Matters

For investors and stakeholders tracking Jazz Pharmaceuticals plc, this filing contains several important signals. This amendment indicates potential updates or corrections to the company's previously filed annual financial statements and disclosures. Investors and analysts will review the amended filing for any changes that may impact their assessment of Jazz Pharmaceuticals' financial health and business operations.

Risk Assessment

Risk Level: low — Jazz Pharmaceuticals plc shows low risk based on this filing. The filing is an amendment to a previous report, suggesting it is a procedural update rather than a significant new event.

Analyst Insight

Review the specific changes made in the 10-K/A filing to understand any updated disclosures or financial information provided by Jazz Pharmaceuticals.

Key Numbers

• 2023-12-31 — Fiscal Year End (The period covered by the annual report)
• 2024-04-26 — Filing Date (Date the amendment was filed)
• 001-33500 — Commission File Number (SEC file number for Jazz Pharmaceuticals plc)

Key Players & Entities

• Jazz Pharmaceuticals plc (company) — Filer of the report
• JAZZ (company) — Trading symbol for Jazz Pharmaceuticals plc
• The Nasdaq Stock Market LLC (company) — Exchange where JAZZ is traded
• Ireland (company) — Jurisdiction of incorporation
• Dublin (company) — Location of principal executive offices
• 2023-12-31 (date) — Fiscal year end
• 2024-04-26 (date) — Filing date

FAQ

Industry Context

Jazz Pharmaceuticals plc operates in the pharmaceutical industry, focusing on developing and commercializing therapies for significant unmet medical needs.

Regulatory Implications

The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing annual reports (Form 10-K) and amendments.

What Investors Should Do

1. Examine the specific changes and additions within the 10-K/A filing.
2. Verify if the amendment impacts previously reported financial figures or business descriptions.
3. Note any new risk factors or disclosures presented in the amended filing.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the annual report.
• 2024-04-26: Filing Date — Date the amendment (10-K/A) was submitted to the SEC.

Year-Over-Year Comparison

This is an amendment to the previously filed 10-K for the fiscal year ended December 31, 2023.

Key Financial Figures

• $0.0001 — istered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Market

Filing Documents

• jazz-20231231.htm (10-K/A) — 1256KB
• exhibit313.htm (EX-31.3) — 6KB
• exhibit314.htm (EX-31.4) — 5KB
• jazz-20231231_g1.jpg (GRAPHIC) — 35KB
• jazz-20231231_g2.jpg (GRAPHIC) — 18KB
• jazz-20231231_g3.jpg (GRAPHIC) — 18KB
• jazz-20231231_g4.jpg (GRAPHIC) — 18KB
• jazz-20231231_g5.jpg (GRAPHIC) — 47KB
• jazz-20231231_g6.jpg (GRAPHIC) — 57KB
• jazz-20231231_g7.jpg (GRAPHIC) — 59KB
• 0001232524-24-000022.txt (&nbsp;) — 2274KB
• jazz-20231231.xsd (EX-101.SCH) — 2KB
• jazz-20231231_lab.xml (EX-101.LAB) — 38KB
• jazz-20231231_pre.xml (EX-101.PRE) — 23KB
• jazz-20231231_htm.xml (XML) — 8KB

Executive Compensation

Executive Compensation 10 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 58 Item 13. Certain Relationships and Related Transactions, and Director Independence 61 Item 14. Principal Accountant Fees and Services 63 PART IV 65 Item 15. Exhibits and Financial Statement Schedules 65

Signatures

Signatures 73 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expect," "plan," "anticipate," "believe," "estimate," "project," "predict," "propose," "intend," "continue," "potential," "possible," "foreseeable," "likely," "unforeseen" and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. We discuss many of these risks, uncertainties and other factors in greater detail under the heading "Risk Factors" in Part I, Item 1A of our 2023 Annual Report on Form 10-K, as filed with the SEC on February 28, 2024. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. You should read this report completely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as required by law, we assume no obligation to update our forward-looking statements publicly, or to update the reasons that actual results could differ materially from

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance DIRECTORS AND EXECUTIVE OFFICERS Our Board of Directors Our board of directors is divided into three classes, designated Class I, Class II and Class III. The term of the Class I directors will expire on the date of our 2024 annual general meeting of shareholders; the term of the Class II directors will expire on the date of our 2025 annual general meeting of shareholders; and the term of the Class III directors will expire on the date of our 2026 annual general meeting of shareholders. At each annual general meeting of shareholders, successors to the directors whose terms expire at that annual general meeting are put forward for election for a three-year term. The following is a brief biography of each member of our board of directors, including their respective ages as of April 22, 2024, with each biography including information regarding the specific experience, qualifications, attributes or skills that led the nominating and corporate governance committee and our board of directors to determine that each member of our board of directors should serve as a director. Class I Directors Continuing in Office Until the 2024 Annual General Meeting Peter Gray , age 69, has served as a member of our board of directors since May 2013 and was appointed as chair of our audit committee in April 2014. On February 23, 2024, Peter Gray notified our board of directors that he will not stand for re-election to our board, when his term expires, at the 2024 annual meeting. He is Chairperson of a privately-held company providing outsourced technology services to the biopharma industry and is a director of a privately-held large molecule development company. He served as Chairperson of the board of directors of UDG Healthcare plc, an international provider of healthcare services, from February 2012 to September 2020. In September 2011, Mr. Gray retired from his position as Chief Executive Officer of ICON plc, a glob

View Full Filing

View this 10-K/A filing on SEC EDGAR